GIP receptor screening tools developed at Sygnature Discovery enable tailored assay development and functional characterization to support GPCR drug discovery. Out custom cell-based systems are optimized for sensitivity, reproducibility and performance in high-throughput formats, accelerating lead identification and optimization for this important metabolic target.
Introduction
Glucose-dependent insulinotropic polypeptide (GIP) receptor, a member of the G protein-coupled receptor (GPCR) family, serves as the primary mediator of GIP’s physiological effects. Through its activation, GIP receptor signalling influences various cellular pathways, including those involved in insulin release, adipogenesis, and gastrointestinal function. Found primarily in pancreatic β-cells and adipocytes, GIP receptors mediate insulin release and impact lipid metabolism, implicating them in the development of obesity and related metabolic disorders. Targeting GIP receptors presents a promising therapeutic strategy for managing obesity and type 2 diabetes, with pharmaceutical interventions offering potential avenues for improving metabolic health and addressing obesity-related complications. Understanding the intricate mechanisms underlying GIP receptor signalling provides valuable insights into the pathophysiology of metabolic diseases and facilitates the development of novel therapeutic interventions.
